Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia

R. V. Fleming, H. M. Kantarjian, R. Husni, K. Rolston, J. Lim, I. Raad, S. Pierce, J. Cortes, E. Estey

Research output: Contribution to journalArticle

Abstract

Fungal infections remain a major cause of treatment failure and death in acute leukemia. New liposomal preparations of amphotericin B are now available. While less toxic, their comparative efficacy and toxicity profiles are unknown. In this study the comparative efficacy and safety of ABLC vs. AmBisome was evaluated in seventy-five patients with leukemia who developed 82 episodes of suspected or documented mycosis, and were treated (1:1) with either ABLC (n=43) or AmBisome (n=39). Both drugs were dosed accordingly from 3 to 5mg/kg/day. Using an intent-to-treat analysis, the overall response to therapy was 27/43 (63%) for ABLC and 15/39 (39%) for AmBisome (p=0.03). Median dose and duration of treatment was 10 days at 3mg/kg for ABLC and 15 days at 4 mg/kg for AmBisome. Acute, not dose-limiting infusion side effects were seen in 70% vs. 36% (p=0.002), ABLC vs. AmBisome. Increase of bilirubin > 1.5 times from baseline was 38% vs. 59%, ABLC vs. AmBisome (p=0.05). ABLC and AmBisome were equally effective for the treatment of suspected or documented fungal infections. While, acute infusion-toxicity was greater with ABLC, infusion toxicity requiring discontinuation was similar for both drugs. AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy.

Original languageEnglish (US)
Pages (from-to)511-520
Number of pages10
JournalLeukemia and Lymphoma
Volume40
Issue number5-6
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Mycoses
Leukemia
Therapeutics
liposomal amphotericin B
Poisons
Liver Function Tests

Keywords

  • Abelcet
  • ABLC
  • AmBisome
  • Amphotericin B
  • Fungal infections
  • Leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. / Fleming, R. V.; Kantarjian, H. M.; Husni, R.; Rolston, K.; Lim, J.; Raad, I.; Pierce, S.; Cortes, J.; Estey, E.

In: Leukemia and Lymphoma, Vol. 40, No. 5-6, 01.01.2001, p. 511-520.

Research output: Contribution to journalArticle

Fleming, R. V. ; Kantarjian, H. M. ; Husni, R. ; Rolston, K. ; Lim, J. ; Raad, I. ; Pierce, S. ; Cortes, J. ; Estey, E. / Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. In: Leukemia and Lymphoma. 2001 ; Vol. 40, No. 5-6. pp. 511-520.
@article{f6822cce3aea4d5c8896d4c8f291c39e,
title = "Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia",
abstract = "Fungal infections remain a major cause of treatment failure and death in acute leukemia. New liposomal preparations of amphotericin B are now available. While less toxic, their comparative efficacy and toxicity profiles are unknown. In this study the comparative efficacy and safety of ABLC vs. AmBisome was evaluated in seventy-five patients with leukemia who developed 82 episodes of suspected or documented mycosis, and were treated (1:1) with either ABLC (n=43) or AmBisome (n=39). Both drugs were dosed accordingly from 3 to 5mg/kg/day. Using an intent-to-treat analysis, the overall response to therapy was 27/43 (63{\%}) for ABLC and 15/39 (39{\%}) for AmBisome (p=0.03). Median dose and duration of treatment was 10 days at 3mg/kg for ABLC and 15 days at 4 mg/kg for AmBisome. Acute, not dose-limiting infusion side effects were seen in 70{\%} vs. 36{\%} (p=0.002), ABLC vs. AmBisome. Increase of bilirubin > 1.5 times from baseline was 38{\%} vs. 59{\%}, ABLC vs. AmBisome (p=0.05). ABLC and AmBisome were equally effective for the treatment of suspected or documented fungal infections. While, acute infusion-toxicity was greater with ABLC, infusion toxicity requiring discontinuation was similar for both drugs. AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy.",
keywords = "Abelcet, ABLC, AmBisome, Amphotericin B, Fungal infections, Leukemia",
author = "Fleming, {R. V.} and Kantarjian, {H. M.} and R. Husni and K. Rolston and J. Lim and I. Raad and S. Pierce and J. Cortes and E. Estey",
year = "2001",
month = "1",
day = "1",
doi = "10.3109/10428190109097650",
language = "English (US)",
volume = "40",
pages = "511--520",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia

AU - Fleming, R. V.

AU - Kantarjian, H. M.

AU - Husni, R.

AU - Rolston, K.

AU - Lim, J.

AU - Raad, I.

AU - Pierce, S.

AU - Cortes, J.

AU - Estey, E.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Fungal infections remain a major cause of treatment failure and death in acute leukemia. New liposomal preparations of amphotericin B are now available. While less toxic, their comparative efficacy and toxicity profiles are unknown. In this study the comparative efficacy and safety of ABLC vs. AmBisome was evaluated in seventy-five patients with leukemia who developed 82 episodes of suspected or documented mycosis, and were treated (1:1) with either ABLC (n=43) or AmBisome (n=39). Both drugs were dosed accordingly from 3 to 5mg/kg/day. Using an intent-to-treat analysis, the overall response to therapy was 27/43 (63%) for ABLC and 15/39 (39%) for AmBisome (p=0.03). Median dose and duration of treatment was 10 days at 3mg/kg for ABLC and 15 days at 4 mg/kg for AmBisome. Acute, not dose-limiting infusion side effects were seen in 70% vs. 36% (p=0.002), ABLC vs. AmBisome. Increase of bilirubin > 1.5 times from baseline was 38% vs. 59%, ABLC vs. AmBisome (p=0.05). ABLC and AmBisome were equally effective for the treatment of suspected or documented fungal infections. While, acute infusion-toxicity was greater with ABLC, infusion toxicity requiring discontinuation was similar for both drugs. AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy.

AB - Fungal infections remain a major cause of treatment failure and death in acute leukemia. New liposomal preparations of amphotericin B are now available. While less toxic, their comparative efficacy and toxicity profiles are unknown. In this study the comparative efficacy and safety of ABLC vs. AmBisome was evaluated in seventy-five patients with leukemia who developed 82 episodes of suspected or documented mycosis, and were treated (1:1) with either ABLC (n=43) or AmBisome (n=39). Both drugs were dosed accordingly from 3 to 5mg/kg/day. Using an intent-to-treat analysis, the overall response to therapy was 27/43 (63%) for ABLC and 15/39 (39%) for AmBisome (p=0.03). Median dose and duration of treatment was 10 days at 3mg/kg for ABLC and 15 days at 4 mg/kg for AmBisome. Acute, not dose-limiting infusion side effects were seen in 70% vs. 36% (p=0.002), ABLC vs. AmBisome. Increase of bilirubin > 1.5 times from baseline was 38% vs. 59%, ABLC vs. AmBisome (p=0.05). ABLC and AmBisome were equally effective for the treatment of suspected or documented fungal infections. While, acute infusion-toxicity was greater with ABLC, infusion toxicity requiring discontinuation was similar for both drugs. AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy.

KW - Abelcet

KW - ABLC

KW - AmBisome

KW - Amphotericin B

KW - Fungal infections

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0035049295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035049295&partnerID=8YFLogxK

U2 - 10.3109/10428190109097650

DO - 10.3109/10428190109097650

M3 - Article

C2 - 11426524

AN - SCOPUS:0035049295

VL - 40

SP - 511

EP - 520

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -